Javascript must be enabled to continue!
A Novel Structurally Stable Multiepitope Protein for Detection of HCV
View through CrossRef
Hepatitis C virus (HCV) has emerged as the major pathogen of liver diseases in recent years leading to worldwide blood-transmitted chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Accurate diagnosis for differentiation of hepatitis C from other viruses is thus of pivotal importance for proper treatment. In this work we developed a recombinant multiepitope protein (rMEHCV) for hepatitis C diagnostic purposes based on conserved and immunodominant epitopes from core, NS3, NS4A, NS4B, and NS5 regions of the virus polyprotein of genotypes 1a, 1b, and 3a, the most prevalent genotypes in South America (especially in Brazil). A synthetic gene was designed to encode eight epitopes in tandem separated by a flexible linker and bearing a his-tag at the C-terminal end. The recombinant protein was produced in Escherichia coli and purified in a single affinity chromatographic step with >95% purity. Purified rMEHCV was used to perform an ELISA which showed that the recombinant protein was recognized by IgG and IgM from human serum samples. The structural data obtained by circular dichroism (CD) spectroscopy showed that rMEHCV is a highly thermal stable protein at neutral and alkaline conditions. Together, these results show that rMEHCV should be considered an alternative antigen for hepatitis C diagnosis.
Title: A Novel Structurally Stable Multiepitope Protein for Detection of HCV
Description:
Hepatitis C virus (HCV) has emerged as the major pathogen of liver diseases in recent years leading to worldwide blood-transmitted chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
Accurate diagnosis for differentiation of hepatitis C from other viruses is thus of pivotal importance for proper treatment.
In this work we developed a recombinant multiepitope protein (rMEHCV) for hepatitis C diagnostic purposes based on conserved and immunodominant epitopes from core, NS3, NS4A, NS4B, and NS5 regions of the virus polyprotein of genotypes 1a, 1b, and 3a, the most prevalent genotypes in South America (especially in Brazil).
A synthetic gene was designed to encode eight epitopes in tandem separated by a flexible linker and bearing a his-tag at the C-terminal end.
The recombinant protein was produced in Escherichia coli and purified in a single affinity chromatographic step with >95% purity.
Purified rMEHCV was used to perform an ELISA which showed that the recombinant protein was recognized by IgG and IgM from human serum samples.
The structural data obtained by circular dichroism (CD) spectroscopy showed that rMEHCV is a highly thermal stable protein at neutral and alkaline conditions.
Together, these results show that rMEHCV should be considered an alternative antigen for hepatitis C diagnosis.
Related Results
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
Hepatitis C virus (HCV) infection, which can cause chronic liver diseases, cirrhosis and hepatocellular carcinoma, is still a major public health problem worldwide. Upon comparing ...
AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C
AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C
INTRODUÇÃO: A detecção de HCV na triagem, em doadores de sangue da Fundação Hemopa, é realizada simultaneamente por um teste sorológico e um teste molecular. No caso de discordânci...
Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease
Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease
AbstractTo clarify the relationship between hepatitis C virus (HCV) genotypes and liver disease, we typed HCV genomes in the sera of 151 blood donors, 180 patients with type C chro...
A11 NEXT STEPS IN MICRO-ELIMINATION: PEER POINT OF CARE HEPATITIS C TESTING IN VICTORIA, BRITISH COLUMBIA
A11 NEXT STEPS IN MICRO-ELIMINATION: PEER POINT OF CARE HEPATITIS C TESTING IN VICTORIA, BRITISH COLUMBIA
Abstract
Background
Canada is currently on target to reach the 2030 WHO goal of hepatitis C virus (HCV) elimination. Continued h...
Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response
Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response
Hepatitis C virus (HCV) is a major human pathogen that requires a better understanding of its interaction with host cells. There is a close association of HCV life cycle with host ...
Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan
Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan
Abstract
Background
Most of Harm Reduction Service (HRS) users represent a crucial high-risk population for blood borne infectio...
Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV
Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV
Abstract
Background
We estimated and characterized the proportion of patients living with HIV (PLWH) who missed hepatitis C (HCV...
RENAL TRANSPLANTATION OFFERS BETTER SURVIVAL IN HCV‐INFECTED END‐STAGE RENAL DISEASE PATIENTS
RENAL TRANSPLANTATION OFFERS BETTER SURVIVAL IN HCV‐INFECTED END‐STAGE RENAL DISEASE PATIENTS
Hepatitis C virus (HCV) infection is known to increase morbidity and mortality in the dialysis population. Renal transplantation is an offered treatment option after a careful pret...

